192TiP Radiological morphological (MF) and radiomic features (RF) of brain metastases in oncogene-addicted advanced non-small cell lung cancer (NSCLC) patients: Diagnostic implications and prognostic role (BRAIN Lung study)

Background: Brain metastases are one of the most important metastatic lesions of advanced NSCLC patients and their incidence is higher in oncogene-addicted patients compared to wild-type ones. Despite the improvement of intracranial response and disease control observed with target therapy, brain metastases are still one of the main negative prognostic factors associated with therapeutic failure and worse quality of life. The radiological and radiomic study of the primary tumor and metastatic lesions is one of the most promising areas of cancer research, not only for their diagnostic implication but also for their potential prognostic and predictive role in many tumor types, including lung cancer. In literature, some data are available on primary brain tumors, but scarce data are available on brain metastases from NSCLC. The identification of specific radiological and radiomic features of brain metastases correlated with oncogene-addicted NSCLC could be a useful diagnostic and prognostic tool in clinical practice. Trial design: The BRAIN Lung is an ongoing multicentric retrospective study conducted on advanced NSCLC patients with brain metastases divided into two cohorts: oncogene-addicted and wild-type patients. Radiological images from magnetic resonance imaging and computed tomography scans of the brain are collected at the time of brain metastases diagnosis (baseline) and during treatment (intracranial best response and progression) and are assessed according to Response Assessment in Neuro-Oncology criteria. The primary objective is the identification of specific MF, RF and their inclusion in a “radiological/radiomic signature," in oncogene-addicted NSLC patients compared to wild-type ones. Secondary objectives include the assessment of the prognostic and predictive role of MF, RF and radiological/radiomic signature at baseline and their variation during treatment, according to their correlation with survival, systemic and intracranial response outcomes in both cohorts. Legal entity responsible for the study: Medical Oncology 2, IRCCS Ospedale Policlinico San Martino. Funding: Has not received any funding. Disclosure: M. Tagliamento: Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: Bristol-Myers Squibb; Travel/Accommodation/Expenses: AstraZeneca; Travel/Accommodation/Expenses: Takeda; Honoraria (self): Novartis; Honoraria (self): Amgen. G. Rossi: Honoraria (self), Honoraria (institution): Bristol Meyer Squibb; Honoraria (self), Honoraria (institution): Roche; Honoraria (self), Honoraria (institution): Amgen; Honoraria (self), Honoraria (institution): Janssen. M. Tiseo: Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eli-Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony: BMS; Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Boehringer Ingelheim; Advisory/Consultancy, Speaker Bureau/Expert testimony: Otsuka; Advisory/Consultancy, Speaker Bureau/Expert testimony: Takeda; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pierre Fabre. C. Genova: Honoraria (self), Honoraria (institution): AstraZeneca; Honoraria (self), Honoraria (institution): Bristol-Myers Squibb; Honoraria (self), Honoraria (institution): Merck-Sharp-Dohme; Honoraria (self), Honoraria (institution): Boehringer-Ingelheim; Honoraria (self), Honoraria (institution): Roche. All other authors have declared no conflicts of interest.